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ABSTRACT  
The identification of the brain regions involved in the neuropharmacological action is a 
potential procedure for drug development. These regions are commonly determined by the 
voxels showing significant statistical differences after comparing placebo-induced with drug-
elicited effects. LORETA is an electroencephalography (EEG) source imaging technique 
frequently used to identify brain structures affected by the drug. The aim of the present study 
was to evaluate different methods for the correction of multiple comparisons in the LORETA 
maps. These methods which have been commonly used in neuroimaging and also simulated 
studies have been applied on a real case of pharmaco-EEG study where the effects of increasing 
benzodiazepine doses on the central nervous system measured by LORETA were investigated.. 
Data consisted of EEG recordings obtained from 9 volunteers who received single oral doses of 
alprazolam 0.25 mg, 0.5 mg and 1 mg, and placebo in a randomized cross-over double-blind 
design. The identification of active regions was highly dependent on the selected multiple test 
correction procedure. The combined criteria approach known as cluster mass was useful to 
reveal that increasing drug doses led to higher intensity and spread of the pharmacologically-
induced changes in intracerebral current density. 
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1. INTRODUCTION 
 The identification of brain regions targeted by neuropsychopharmacological agents is a 
newly-advanced and promising tool for drug discovery and development. Neuroimaging 
techniques applied to neuropharmacology provide information concerning the regional 
specificity of drug action, its time course, dose-response effects, and effects on cognition [17].  
 Localizing neural activity in the brain, both in time and in space, is an essential step to 
advance the understanding of cerebral function. Several non-invasive neuroimaging techniques 
allow the study of the cerebral functional activity: positron emission tomography (PET), single 
photon emission computed tomography (SPECT), functional magnetic resonance imaging 
(fMRI) and EEG/MEG source imaging. Some of these methods (PET, SPECT and fMRI) 
measure neuronal activity indirectly by quantifying glucose metabolism or cerebral blood flow 
[11]. The most widely used method in neuropsychopharmacology is EEG source imaging. This 
technique localizes the electrical brain sources responsible for the scalp potential distribution by 
estimating the solution to the so-called inverse problem. Scalp voltage data (EEG) is recorded 
after drug/placebo administration, a procedure known as pharmaco-EEG. fMRI has also been 
used to examine the acute effects of various drugs on neural activity [16], an approach that has 
been termed pharmacological MRI or phMRI. Regarding EEG- and MEG-based source imaging 
techniques, the EEG rhythms reflect the activation and inactivation of bidirectional connections 
between several cortical and subcortical structures and thus a single dipolar source indicates the 
centroid of the distributed cortical sources generating the EEG rhythms [21]. An alternative 
approach for modeling these sources is known as LORETA (low resolution electromagnetic 
tomography) which uses thousands of dipolar sources within a 3D brain model. LORETA takes 
into account anatomical constraints and composes the linear inverse solution that maximizes the 
synchronization among neuronal populations in terms of orientation and strength [22].  
 EEG/MEG source imaging is useful to study the cortical sources of EEG rhythms and 
evoked potentials after drug administration [4-5, 14]. Indeed, LORETA has been used for the 
evaluation and characterization of the pharmacodynamics of different psychotropic drugs [28]. 
 EEG source imaging, as every neuroimaging method, has its own strengths and 
weaknesses.  It is a cost-effective and movement-tolerant technique and provides data with high 
temporal resolution but its spatial resolution is limited compared to that of phMRI. Ultimately, 
all the neuroimaging techniques have common issues since the brain regions involved in 
pharmacological action are determined by the voxels showing significant differences compared 
to controls or placebo. Following this methodology, an intracerebral effect map is constructed 
by applying a thresholding rule to the resulting statistics, and statistical maps or images are 
created to assess the pharmacological effect. Naive thresholding of 6239 voxels used by the 
LORETA approach at 5% statistical significance is inadequate because up to 312 false positives 
would be expected in null data. False positives must be controlled over all tests but there is no 
single measure of type I error in multiple testing problems. The standard measure is the 
probability of any type I error, the family-wise error rate (FWE). However, other alternative 
procedures are constantly being developed such as the false discovery rate (FDR) error metric 
that inspects the expected ratio of rejected hypotheses that are false positives [8]. Several FWE 
testing procedures have been used in functional neuroimaging, in particular in the fMRI field 
[18], such as the Bonferroni approach or other methods based on the maximum statistic 
(minimum p-value) distribution, the random field theory, or resampling procedures [20]. 
However, only two approaches have been reported in the literature to control the FWE in 
pharmaco-EEG/MEG source imaging techniques: the nonparametric permutation test based on 
voxel intensity [19], and the minimum cluster size based on the binomial test [12]. The former is 
the multiple comparison correction procedure implemented in the LORETA statistical package 
and thus the most commonly used approach in pharmaco-EEG studies [1, 14, 24, 30]. The 
performance of voxel intensity-based tests has already been examined and validated by Monte 
Carlo simulations of noisy cluster images with multiple intensities and diameters using the same 
permutation statistical tests [15]. The binomial test has also been applied in pharmaco-EEG 
studies, especially when drug effects are weak [3, 27, 29].  
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 The main aim of this paper was to evaluate multiple comparison procedures when 
analyzing the effect of increasing drug doses on brain regions involved in the pharmacological 
action. We assessed changes in intensity, in spread of the target brain area, and in both effects 
combined. The drug analyzed in this study was alprazolam, which is a potent short-acting 
benzodiazepine. It is already known that varying a benzodiazepine dose leads to changes in the 
topographical EEG-based maps [6]. Thus, changes on the tomographical analysis are also 
expected. Three FWE methods for multiple testing were compared for the assessment of three 
increasing acute oral doses of alprazolam. Two of them are commonly used in pharmaco-
EEG/MEG neuroimaging: the nonparametric permutation test based on voxel intensity and the 
minimum cluster size based on the binomial test. A third procedure for FWE multiple testing 
was also considered: the nonparametric permutation test based on a cluster mass combining 
function [10]; widely used in the fMRI field. This method allows determining regions whose 
extent and intensity are sufficiently large, even when they are not significant by intensity or 
extent alone. Cluster mass performance is already known [15] but, to the best of our knowledge, 
has never been used before for pharmaco-EEG/MEG neuroimaging.  
2. METHODOLOGY 
2.1. Study design 
 Nine young healthy male volunteers aged between 20 and 32 years (mean age 23 years) 
were recruited for the study. Medical history was checked for absence of psychiatric and 
neurological disorders, and after medical examination, laboratory tests, ECG, and urinalysis 
were found to be normal. Volunteers were not allowed to take any medication for 2 weeks 
before the study and they abstained from alcohol, tobacco and caffeinated drinks for 48h before 
each experimental day. Experimental days were separated by 1-week washout period. 
 The study was approved by the local Ethics Committee and the Spanish Ministry of Health, 
and was conducted in accordance with the Declaration of Helsinki and the guidelines of Good 
Clinical Practice. All volunteers gave their written informed consent to participate. Single oral 
doses of placebo and 0.25, 0.5 and 1.0mg of alprazolam, packaged into identical capsules, were 
administered in a balanced order according to a double-blind, randomized, cross-over and 
placebo-controlled design. Upon arrival in the laboratory under fasting conditions, a urine 
sample was obtained to test for illicit drug intake, electrodes were applied to the scalp and 
medication was given. Volunteers were seated in a comfortable reclining chair in a sound-
attenuated and electrically shielded chamber during each recording session, while spontaneous 
EEG signals with eyes closed were recorded under continuous vigilance. 
 The EEG recordings were acquired from 19 electrodes placed on the scalp according to the 
international 10/20 system on the following locations: Fp1, Fp2, F7, F3, Fz, F4, F8, T3, C3, Cz, 
C4, T4, T5, P3, Pz, P4, T6, O1 and O2, referenced to averaged mastoids. Additionally, vertical 
and horizontal EOG (VEOG and HEOG, respectively) signals were recorded. The VEOG was 
obtained from mid-forehead (2.5 cm above the interpupillary line) and from the average of two 
electrodes below the eyes (2.5 cm below the interpupillary line), whereas the HEOG signal was 
acquired from the outer canthi. The EEG and EOG signals were recorded at a sampling 
frequency of 500Hz by means of Neuroscan Synamps amplifiers and analogically filtered 
between 0.1 and 50Hz. Finally, the EEG and EOG data were offline resampled with a resulting 
sampling frequency of 100Hz and a low-pass filtering up to 40Hz. Three-minute EEG was 
recorded before drug intake (baseline) and at +30min, +45min, +1h, +1.5h, +2.5h, +4h, +6h and 
+8h after drug administration. To ensure the quality of the recordings, electrode impedances 
were checked before each acquisition and were kept below 5kΩ. 
2.2. Artifact minimization 
 Artifacts were dealt with by using a two-step process. Its first stage involved an ocular 
contamination reduction process based on blind source separation (BSS). BSS-based reduction 
of ocular artifacts has proven to achieve more reliable tomographic maps than minimization 
based on regression [26]. EEG signals were segmented into 5-s epochs. A second stage 
consisting of an automatic artifact (saturation, muscular and movement) rejection procedure was 
applied as described by Anderer et al. [2]. 
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 BSS-based techniques decompose the multichannel EEG and EOG data into a mixture of 
source signals and second-order statistics are usually sufficient to solve the linear BSS problem 
if temporal information is taken into account. The SOBI (Second Order Blind Identification) 
algorithm [7], based on eigenvalue decomposition of a linear combination of several time 
delayed covariance matrices, was applied in this study. Finally, after the automatic detection of 
ocular sources, carried out using frequency and scalp topographical aspects of the source 
components as described by Romero et al. [25], the corrected EEG signals were reconstructed 
from the remaining source components.  
2.3. LORETA analysis 
 Following the two-step artifact minimization, the artifact-free epochs were considered for 
further analysis: under the administration of placebo (30.38 ± 6.64 epochs), alprazolam 0.25 mg 
(29.03 ± 8.67 epochs), alprazolam 0.5 mg (32.05 ± 4.71 epochs), and alprazolam 1 mg (27.93 ± 
8.03 epochs). The LORETA technique was used to estimate the three-dimensional intracerebral 
current density function from the voltage values recorded at the scalp electrodes. Specifically, 
the sLORETA (standardized low resolution brain electromagnetic tomography) version of the 
program was employed in this study, as it provides the lowest possible localization error when 
testing point sources [22]. The 3D localization maps were obtained by calculating a location-
wise inverse weighting of the minimum-norm least-squares inverse solution with estimated 
variances. This EEG source imaging technique restricts the solution to 6239 cortical grey matter 
voxels with a resolution of 5mm (spatial resolution of 0.125cm3) according to the digitized MNI 
(Montreal Neurological Institute) Human Brain Atlas [9]. 
 In a first step, the current density values were estimated based on the EEG cross-spectral 
matrix and then squared for each voxel in the following frequency bands: delta (0.5 to 3.5 Hz), 
theta (3.5 to 7.5 Hz), alpha1 (7.5 to 10.5 Hz), alpha2 (10.5 to 13 Hz), beta1 (13 to 16 Hz), beta2 
(16 to 20 Hz), beta3 (20 to 25 Hz), beta4 (25 to 30 Hz), and beta5 (30 to 35 Hz). To evaluate 
differences between drugs and placebo, paired-sample t-tests were computed for the baseline-
corrected (subtraction of the baseline values) and log-transformed LORETA power values in 
each voxel and for each frequency band at the different time points. The large number of 
statistical tests that were carried out simultaneously due to the number of voxel-wise 
comparisons resulted in an increased risk of type I errors. To control for this increased risk of 
false positives, the three multiple comparison correction methods mentioned above were applied 
to the data to identify the number of significant voxels in each region of interest. As explained 
in the introduction, the first two methods have been commonly used in pharmaco-EEG 
neuroimaging, whereas the latter comes from the fMRI field and has not been applied before to 
this neuroimaging approach. 
2.3.1. Nonparametric permutation test based on voxel intensity or peak height 
 The nonparametric permutation test [19] is a single threshold test based on the theory of 
randomization tests. In particular, the voxel intensity procedure calculates the critical t-value 
using a random sample of all the possible permutations and estimates the distribution of the 
maximum t statistic. Under the null hypothesis, data labels can be permuted without altering the 
distribution of the test statistic of interest. Corrected p-values or threshold statistical voxel 
intensities can be calculated from this empirical distribution. This distribution depends on the 
correlation structure of the t-statistic, and is considered a useful method to set the critical t-
threshold. 
2.3.2. Minimum cluster size using the binomial test 
 A single null hypothesis for omnibus significance based on the binomial test was also 
employed. This method considers the size of the target region and calculates the minimum 
number of contiguous voxels constituting a suprathreshold region by means of a binomial test 
[12]. For the 6239 voxels obtained by LORETA and an overall significance of 5%, a voxel 
could be considered significant if it belonged to a cluster with at least 341 voxels according to 
the binomial theorem. Clusters were built as a set of contiguous voxels whose t-value exceeded 
the corresponding threshold (t=2.306 in this study, corresponding to a significance of 0.05 and 8 
degrees of freedom) considering an 18-connectivity scheme, that is, neighbors sharing at least 
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one edge with the considered voxels.. Hence, the active region derived from this method has to 
be large and compact enough to be considered a consequence of the drug effects and not of 
mere statistical chance.  
2.3.3. Nonparametric permutation test based on cluster mass combining function 
 A combined statistic of voxel intensity and cluster size can be used to benefit from the 
strength of both FWE measures. Thus, the cluster mass combining function can produce 
significant results when both intensity and cluster size are marginally significant [10, 15]. In 
particular, the cluster mass is calculated by adding up the intensity values exceeding the t-value 
threshold of all the voxels in a cluster. This summation is computed over all the clusters and 
considering all the possible permutations, so that an empirical distribution of the largest cluster 
mass values obtained can be used to find FWE-corrected p-values for the clusters derived from 
the original labeling. 
 
Fig. 1: Time course of average current source density values (µA/mm2) obtained in the different brain lobes after 
baseline and placebo subtraction for the a) alpha1 and b) beta1 bands. Different y-axis scales were used for the alpha1 
and beta1 graphs. The doses of alprazolam are depicted in different shades of grey. Statistical comparisons between 
doses of alprazolam are depicted using the following symbols: circle, 1 mg vs 0.25 mg; asterisk, 1 mg vs 0.5 mg; and 
triangle, 0.5 mg vs 0.25 mg.  
- 6 - 
 
 
3. RESULTS 
 The sedative-hypnotic effect of alprazolam is characterized by: 1) a specific decrease in the 
absolute power of the slow alpha activity (alpha1), whereas the fast alpha activity (alpha2) 
remains unchanged; and 2) a generalized increase of the absolute power of beta activity [28]. 
 Figure 1 shows the time course of the LORETA net current source density corresponding 
to the different doses of alprazolam after subtracting baseline and placebo values for the alpha1 
and beta1 bands. These results indicate that alprazolam-induced effects were stronger in the 
alpha1 than in the beta1 band. The alpha1 decreases were emphasized in the parietal and 
occipital lobes, whereas the beta1 increases were accentuated in the frontal, parietal and limbic 
lobes. Ascending-dose effects were observed in all brain lobes for both frequency bands. 
However, depending on inter-subject variability of the LORETA current density values, small 
changes associated with low variance led to significant activations whereas large differences 
with perceptible variance were not significant. Statistical tests between the LORETA values 
corresponding to the placebo and alprazolam doses were performed at each voxel and recording 
time for the two frequency bands (alpha1 and beta1) which are primarily affected by 
alprazolam.  
 Note that the acquisition of EEG signals at different times after alprazolam administration 
allowed the assessment of the time course of target brain regions associated with significant 
changes in intracerebral current density. Moreover, this time monitoring allowed the 
identification of the onset and the duration of the pharmacological effect in the alpha1 and beta1 
frequency bands.  
 Three-dimensional statistical maps were obtained to test for differences in tomography 
between the binomial and voxel intensity multiple comparison correction methods. These maps 
showed the target regions at different times after the administration of the three alprazolam 
doses (0.25 mg, 0.5 mg and 1 mg in figures 2, 3 and 4, respectively) compared with placebo, for 
the alpha1 and beta1 rhythms. Finally, a color gradient was used to show the statistically 
significant regions after applying the abovementioned correction methods. 
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Fig. 2: Time course of the intracerebral effects after 0.25 mg alprazolam compared with placebo (n=9). The images, 
visualized from different perspectives, show statistical parametric maps based on t values of the differences between 
alprazolam- and placebo-induced changes with respect to baseline. Different shades of color were used to clarify the 
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Fig. 3: Time course of intracerebral effects after 0.5 mg alprazolam compared with placebo (n=9). See 
figure 2 legend for abbreviations and more information. 
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3.1. Nonparametric permutation test based on voxel intensity 
 The multiple comparison correction based on the voxel intensity procedure was performed 
using all the 512 possible randomizations [19]. The analysis at the time point when the 
maximum effect was expected (around 60 and 90min after drug administration) showed little or 
no significant differences (decreases in dark blue and increases in dark red) for the 0.25 mg 
dose, neither in alpha1 nor in beta1. On the other hand, 1 mg of alprazolam caused a significant 
 
Fig. 4: Time course of intracerebral effects after 1 mg alprazolam compared with placebo (n=9). See figure 2 legend 
for abbreviations and more information. 
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decrease of alpha1 activity located mainly in the temporal and occipital lobes. Regarding the 
effects in the beta1 band, a significant increase in intracerebral power density was observed 
after the 0.5 mg dose. Although it was located between the frontal and parietal lobes, this 
increase shifted towards the parietal lobes after the 1 mg dose. 
 Regarding the effect duration, the effects of the 1 mg dose appeared in alpha1 30 minutes 
after intake, dropped at 150 minutes, and a small action still remained even at 8 hours after 
administration. In contrast, the 1 mg effect in beta1 was shorter: it arose at 45 minutes and 
vanished at 90 minutes. Nevertheless, at the low and medium alprazolam doses, the time course 
of drug-induced changes was not coherent with the known pharmacological effect. For instance, 
no significant effect was obtained for beta1 at any time after the lowest dose administration. 
Moreover, a very small significant change was observed in alpha1 after administration of the 
low dose. This effect appeared in the right hemisphere at 60 minutes, disappeared at 90 minutes, 
but then reappeared in the left hemisphere at 150 minutes. Similar results were obtained for 
alpha1 and especially beta1 following the medium dose administration: the effect appeared, then 
vanished, and reappeared later, several hours after drug administration. 
3.2. Minimum cluster size using the binomial test 
 For the binomial test method, voxels were colored within a contiguous region composed of 
more than 341 voxels with t-values exceeding a threshold of 2.306 (corresponding to a 
significance level of 0.05). The results in figures 2, 3 and 4 show how the intracerebral target 
regions (drawn in any color) expanded when the threshold t-value decreased, for both alpha1 
and beta1 bands. In other words, when the threshold t-value is less restrictive, more voxels 
accomplished the condition resulting in larger significant areas. In addition, the correspondence 
between the ascending dose effect and the increasingly larger significant brain regions was 
clearly more marked for the binomial test than for the voxel intensity method, and even the 0.25 
mg dose showed a significant region in the former case.  
 With respect to the figures, the target brain regions indicated a more logical temporal 
progression: for example, the effect induced in alpha1 by the medium dose did not show an 
intermittent behavior at consecutive time points as happened with the voxel intensity procedure. 
However, the binomial test method is considered a weak control of the FWE. Although it is 
useful for detecting whether there is any pharmacological effect, it is not suitable for the 
localization of the target brain regions.  
3.3. Nonparametric permutation test based on cluster mass combining function 
 Table 1 shows the results of the cluster mass combining function after applying this test for 
the alpha1 and beta1 bands. Significant suprathreshold clusters were found by this combined 
test at practically all time points after the intake of the medium and high alprazolam doses 
compared with placebo. At the remaining 0.25 mg dose, significant maps were obtained for 
alpha1 between 60 and 150 minutes. 
TABLE 1: Cluster mass function and p-values of alprazolam- versus placebo-induced changes in the 
alpha1 and beta1 powers for three different doses. Several time points after drug administration were 
considered. Cluster-based statistics were found setting a threshold corresponding to a significance 
level of 0.05 to define the cluster area. 
 
TIME 
ALPRAZOLAM 
0.25mg 
ALPRAZOLAM 
0.5mg 
ALPRAZOLAM 
1mg 
Cluster 
mass 
p-value 
cluster 
mass 
Cluster 
mass 
p-value 
cluster 
mass 
Cluster 
mass 
p-value 
cluster 
mass 
A
L
P
H
A
1 
30’ 260 0.096 0 0.976 12528 0.002 
45’ 104 0.217 5466 0.006 13584 0.002 
60’ 2717 0.002 6257 0.010 14884 0.002 
90’ 1292 0.012 12767 0.002 25801 0.002 
150’ 2203 0.025 4880 0.002 10107 0.002 
240’ 795 0.072 1014 0.022 8657 0.006 
360’ 577 0.057 328 0.057 9884 0.002 
480’ 204 0.205 561 0.072 10511 0.002 
- 11 - 
 
 
B
E
T
A
1 
30’ 224 0.225 7704 0.006 312 0.205 
45’ 134 0.154 4809 0.006 10205 0.002 
60’ 297 0.131 8749 0.002 13286 0.002 
90’ 447 0.082 2974 0.020 7640 0.012 
150’ 0 0.984 1806 0.029 3220 0.006 
240’ 1 0.705 2734 0.006 1872 0.010 
360’ 37 0.369 2504 0.014 1116 0.029 
480’ 0 0.941 1013 0.049 217 0.150 
 
TABLE 2: Nonparametric permutation tests (partial voxel intensity and combined cluster mass) 
applied in order to show the statistical changes for alpha1 and beta1 powers at 90min and 60min after 
administration respectively, in the brain regions involved in the pharmacological action after an 
increase of the alprazolam dosage. Statistics and cluster values were found setting a threshold 
corresponding to a significance level of 0.05 to define the cluster area. 
COMPARED 
TREATMENTS 
ALPHA1 (90min after administration) 
voxel intensity  cluster mass 
Extreme            
t-value 
p-value  
Cluster 
mass value 
p-value 
0.25mg vs placebo -6.232 0.043  1292 0.012 
0.5mg vs placebo -13.610 0.002  12767 0.002 
1mg vs placebo -16.538 0.002  25801 0.002 
      
COMPARED 
TREATMENTS 
BETA1 (60min after administration)  
voxel intensity  cluster mass 
Extreme            
t-value 
p-value  
Cluster 
mass value 
p-value 
0.25mg vs placebo 4.053 0.107  297 0.131 
0.5mg vs placebo 12.170 0.002  8749 0.002 
1mg vs placebo 15.119 0.002  13286 0.002 
 
 The suprathreshold clusters detected by the cluster mass method corresponded to target 
brain regions where peak intensity was significant. Cluster mass showed clearly the effect of 
ascending doses as a function of time: higher values were obtained from 45 or 60 minutes until 
90 or 150 minutes after the administration for any dose, and these values increased with dose 
(see table 1). Table 2 shows the results of partial voxel-intensity and combined nonparametric 
permutation tests for alpha1 and beta1 powers after alprazolam administration, at 90 and 60 
minutes respectively, compared with placebo. Note that the extreme t-values increased with the 
dose and the corrected p-values produced by the cluster mass test showed that significant 
clusters were found for all the comparisons except for beta1 in 0.25 mg vs placebo. These 
results indicated that the effect of an ascending-dose of alprazolam produced both an increase of 
the intensity and an enlargement of the brain regions involved in the drug action.  
 According to these results, it could be concluded that the LORETA statistical probability 
maps and the brain regions considered suprathreshold after drug administration depended 
heavily on the statistical significance level. Likewise, the minimum voxel intensity, the 
minimum cluster mass, and their corrected p-values were conditioned by the selected 
significance level. Figure 5 shows the cluster mass value (integral of suprathreshold intensities 
within a cluster) as a function of different significance levels (from 0.05 to 0.001) for alpha1 
and beta1 powers, and evidences how cluster mass values decreased monotonically with lower 
values of significance level. A similar effect, associated with an ascending-dose of the drug, was 
found for all the significance levels: an increase of the alprazolam dosage entailed both a rise in 
the intensity and a spread of the drug-targeted areas. 
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4. DISCUSSION 
 The identification of the brain structures involved in pharmacological action is a promising 
tool to investigate and develop new drugs. The usual procedure used to identify target voxels in 
pharmaco-neuroimaging is to perform voxelwise hypothesis tests (between drug and placebo 
conditions) and to threshold the resulting statistical image. However, the literature reports 
several different approaches concerning the thresholding of the obtained statistical tomographic 
maps. Whereas conservative methods which allow for a fairly accurate localization of the target 
area have been employed [14, 24], other less conservative techniques have been used to show 
weaker drug effects [3, 29]. This duality is accentuated when spontaneous EEG is used because, 
unlike evoked potentials, the location of the cerebral generators is less clear for spontaneous 
EEG and the interpretation of results is much more open and less spatially restricted. 
 One of the most common conservative methods is the Bonferroni correction, where each 
voxel is tested at a significance level divided by the total number of voxels (comparisons). This 
correction would increase the t-value threshold from 2.306 to 10.077 (1 vs. 6239 voxel 
comparisons), and consequently the activity level associated with pharmacological effect would 
have to be extremely strong to exceed the adjusted threshold. One usual way to overcome this 
issue is the a priori definition of regions of interest (ROI) where the drug effect is expected, 
however such definition is feasible for evoked potentials but not when dealing with spontaneous 
activity. 
 In EEG/MEG-based neuropsychopharmacology only the voxel intensity and the binomial-
based cluster size tests have been used to date. Nonparametric permutation tests are based on 
setting the critical threshold according to the empirical null distribution of the test statistic of 
interest. This is ascertained directly from the observed data, although its calculation requires a 
considerable computational effort. It is important to note that, although each voxel is tested 
independently of its neighbors, important drug-induced differences are expected in the spatially 
contiguous voxels, and the nonparametric permutation method based on cluster mass takes this 
information into account to look for compact regions of voxels where the effect is significant. 
Alternatively, a simple method like the binomial test can be applied to obtain the minimum 
number of contiguous voxels that have to exceed the threshold to be considered significant. 
However, the binomial test is a weak control over the FWE and can only indicate the presence 
of activation. In spite of that, these weak FWE control few methods, commonly named omnibus 
tests, are useful for detecting the existence of any pharmacological effect regardless of location 
of these effects [23]. 
 Several works have evaluated different multiple comparison procedures in fMRI analysis 
[13, 18, 20]. In general, multiple comparison correction procedures can be classified into 
 
Fig. 5: Cluster mass calculated as a function of different values of significance level (α ) in alpha1 and beta1 powers 
at 1hour after the administration of different doses of alprazolam compared with placebo. 
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parametric (based on random field theory) and nonparametric statistics. Parametric statistics are 
more robust but require a Gaussian distribution, whereas nonparametric statistics have the 
advantage of being distribution-independent as well as insensitive to extreme values or outliers, 
at an additional computational cost.  
 Among the evaluated correction procedures, the conservative approach of the 
nonparametric permutation test based on voxel intensity allowed the determination of the 
targeted brain region after alprazolam administration as compared with placebo. The alpha1 
LORETA power decrease was mainly located in the temporal lobe, and the beta1 LORETA 
power increased in the parietal lobe. However, the brain regions involved did not show any 
coherent time or ascending-dose course. On the one hand no differences were obtained for 0.25 
mg neither in alpha1 nor in beta1; on the other, significant effects usually appeared and 
disappeared intermittently at consecutive times, reappearing when the drug effect was 
theoretically very weak. 
 According to these results, the interpretation of the statistical tests can be determined by 
subjectively adjusting the thresholds (using a more or less conservative multiple comparison 
correction procedure) to obtain desirable results. In this sense, better results were obtained using 
the voxel intensity approach when the drug effect was substantial (1 mg dose) in contrast to the 
results obtained when the effect was weaker (0.25 and 0.5 mg doses). 
 The aim of this paper was to investigate if the pharmacological effects on the brain after an 
ascending dose were larger in extent, intensity or both. The cluster mass, calculated as the 
integral of suprathreshold intensities within a cluster, is a theoretical test statistic which 
combines spatial extent and peak height intensity [15]. It is worth noting that temporal and 
ascending-dose effects were clearly revealed by the cluster mass statistic (see table 2). These 
results were found for different significance levels, indicating that although statistics and 
cluster-based parameters depended on the significance level, the conclusion was robust: an 
increase in alprazolam dose occasioned both a rise in the intensity and a spread of the brain 
regions involved in the pharmacological action. 
 Finally, the nonparametric methods analyzed in this study were found to be appropriate and 
valuable tools to objectively assess the impact dose on the target brain regions. Cluster mass 
provided very useful information on the pharmacological effect with ascending doses. As a 
matter of fact, cluster mass could be considered a complementary measure to the voxel intensity 
and cluster size tests. In this way, the cluster mass value associated with both intensity and brain 
area was coherent with dose level and theoretical time intervals at which maximum effects are 
expected. 
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